Nanexa - kommende stor aftale med novo?
-
Fortsatt god tolerabilitet av NEX-22 vid 30 mg dos av liraglutid i NEX-22 studien
https://www.nordnet.dk/markedet/nyheder/f97b7c72-bc6c-41d2-8781-7980870d34e7
-
Nanexa får Late Breaking Abstract godkänt till ADA-kongressen i Chicago i juni https://www.swedbank-aktiellt.se/telegram/EApMxkua
-
Kommende events Nanexa
The first event is the Drug Delivery & Formulation (DDF) Summit, Berlin, Germany
where Joel Hellrup today, June 3, presents: "PharmaShell
- The high drug load delivery system enabling thenext generation long-acting injectables through atomic layer precision."Nanexa will then continue its international presence at the following events:
BIO International Convention in Boston, USA - a forum for creating strategic partnerships and licensing opportunities (June)
American Diabetes Association (ADA) Scientific Sessions in Chicago, USA - where the company's Phase I data for NEX-22 has been accepted as a Late Breaking Abstract and will be presented as a poster (June)
Controlled Release Society (CRS) Annual Meeting in Philadelphia, USA - where Nanexa
will have a one-hour oral presentation on PharmaShell (July) -
Eli Lilly bekræfter, der er mere end bare stærk interesse i teknologi præcis som Nanexas omkring diabetes/obesity, og at en aftale med Novo (eller andre), vil indeholde voldsomme indtægter:
Den særdeles sammenlignelige potentielle aftale har fået Camurus til stige små 9 milliarder SEK i markedsværdi - havde Nanexa en markedsværdi på 9 milliarder fremfor de nuværende små 300 millioner, ville kursen være +50.
CEO'en forklarer under seneste præsentation, hvorfor denne Eli Lilly-aftale ikke kunne have været indgået med Nanexa:
"Der findes jo andre firmaer, vi også diskuterer med - også rigtig, rigtig store i diabetes og obesity - som siger, denne eksklusivitet (med Novo) ligger i vejen for dem." Herefter henviser han til et snævert felt, der inkluderer Novo Nordisk.
Vigtigste budskab for denne præsentation er i følge CEO'en, at samarbejdet med Novo går særdeles godt, og at der ses frem mod licensforhandling, når evalueringen er færdig.
Hvorfor skulle Novo fortsætte samarbejdet omkring evaluering/validering i nu snart 2½ år, hvis de ikke fortsat er interesserede i teknologien?
Nanexas fase I data der præsenteres som Late Breaking Abstract på American Diabetes Association (ADA) Scientific Sessions næste uge, vil være tilgængeligt på ADAs hjemmeside fredag (13/6) eftermiddag:
BIO International Convention 2025 - a forum for creating strategic partnerships and licensing opportunities - er fra 16/6 til 19/6:
-
Nanexa: Highlights den kommende uge
16/6-19:6 Deltagelse Bio International Convention
20/6-23/6: Late breaking Abstract poster presentation. ADA Congress (American Diabetes Association) https://professional.diabetes.org/scientific-sessions
Samt yderligere formidling JournalDiabetes website formentlig under "Ahead of Print" i forbindelse med eller efter kongressen. https://diabetesjournals.org/diabetes
-
Det lader til at skride planmæssigt frem mod en aftale; PharmaShell udvalgt som en af de 3 bedste teknologier på BIO 2025 og CEO'en virker i videoen til at være i fortrinligt humør, før data præsenteres på ADA kongressen denne søndag kl. 19:30.
The team at Nanexa AB have thoroughly enjoyed our time at this year's BIO International Convention in Boston. We've had many fantastic, fruitful conversations with new, old and potential PharmaShell… | Nanexa AB
The team at Nanexa AB have thoroughly enjoyed our time at this year's BIO International Convention in Boston. We've had many fantastic, fruitful conversations with new, old and potential PharmaShell partners, and have also had the time to present precisely how it works in the context of our NEX-22 asset, a formulation of liraglutide which we believe will bring lasting and thus improved effects to diabetes patients. As the event wraps up, we are gearing up for our second conference of the week, and will soon be on our way to this year's American Diabetes Association event in Chicago. We would also like to give a special thanks to MJH Life Sciences' Chris Spivey, who named PharmaShell as one of his top 3 technologies on display at BIO. Watch the full video interview with our CEO, David Westberg, here: https://lnkd.in/gGsmmmfF
LinkedIn (www.linkedin.com)
The team at Nanexa AB have thoroughly enjoyed our time at this year's BIO International Convention in Boston.
We've had many fantastic, fruitful conversations with new, old and potential PharmaShell partners, and have also had the time to present precisely how it works in the context of our NEX-22 asset, a formulation of liraglutide which we believe will bring lasting and thus improved effects to diabetes patients.
As the event wraps up, we are gearing up for our second conference of the week, and will soon be on our way to this year's American Diabetes Association event in Chicago.
We would also like to give a special thanks to MJH Life Sciences' Chris Spivey, who named PharmaShell as one of his top 3 technologies on display at BIO. Watch the full video interview with our CEO, David Westberg, here: https://lnkd.in/gGsmmmfF
-
Poster fra ADA uploadet af Nanexa
-
Prøver med billede
-
Nanexa Signs Continuation of Feasibility Agreement with Major Pharmaceuticals Company to Investigate PharmaShell
Long-Acting Formulations in a Multi-Billion USD Market
Nanexa Signs Continuation of Feasibility Agreement with Major Pharmaceuticals Company to Investigate PharmaShell® Long-Acting Formulations in a Multi-Billion USD Market - Nanexa AB
The collaboration provides further proof that PharmaShell atomic layer deposition technology is of interest to major pharma companies. Nanexa is poised for further partnerships in the treatment of other chronic conditions.
Nanexa AB (nanexa.com)
-
Der indikeres stadig aftaler i 2025. Ovenstående feasibility aftale (ikke NN) angives til et ca. 3 mia USD produkt. Forhandlinger med NN lader til at kunne bekræftes i kraft af Nanexa er forpligtet til at kommunikere ophør. Lyt selv og vurder i 2 kvartal interview. https://www.youtube.com/watch?v=w5Vbi_qcQ6w
-
Tinyreply har på Reddit lavet en fin opsamling Nanexa's nuværende situation september 2025. Der ser ret interesant ud. Umiddelbart synes Nanexa at have kvaliteter som konkurrenterne ikke kan matche. Jeg har lagt min kommentar øverst i feltet da der ikke længere er ret meget aktivitet i tråden. https://www.reddit.com/r/aktietips/comments/1ngsxpc/står_nanexa_foran_et_gennembrud/
-
Pfizer på vej til at købe Metsera for at få fingrene i deres Long Acting Injectable og få en vej ind i fedmemarkedet.
https://finance.yahoo.com/news/pfizer-closes-7-3-billion-040417987.html -
API mængder. Bemærk fra Metsera præsentation. På flere fora diskuteres API mængder bl.a. som havende stor betydning for produktions omkostninger.
-
Screendump fra Discord Nanexa forum. Oprindelig fra Metsera presentation.
-
Nanexa har opdateret clinical trials til COMPLETED 22/9
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind